<a href=GSK” height=”300″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/pharma/GSK_HQ.jpg” style=”padding: 10px” width=”234″ />

GlaxoSmithKline’s (GSK) global HIV business ViiV Healthcare has completed the previously announced acquisition of HIV R&D assets from Bristol-Myers Squibb.

The acquisition of Bristol-Myers’ late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets follows antitrust approval by the relevant regulatory authorities in the US.

Under the deals, ViiV Healthcare bought late-stage HIV R&D assets from Bristol-Myers Squibb for $317m.

The late stage assets include fostemsavir (BMS-663068), which is an attachment inhibitor currently in Phase III development for heavily treatment experienced patients.

The second late stage asset is a maturation inhibitor (BMS-955176) that is currently in Phase IIb development for both treatment-naive and treatment experienced patients.

The deal also covers a back-up maturation inhibitor candidate (BMS-986173).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ViiV Healthcare will provide up to $518m in potential development and regulatory milestone payments for Bristol-Myers’ clinical assets, in addition to $587m for the discovery and pre-clinical programmes.

It will also pay sales-based milestone payments of up to $750m for each of the clinical assets and up to $700m for each of the discovery and pre-clinical programmes.

The purchase includes a novel biologic (BMS-986197) with a triple mechanism of action, an additional maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor that are currently in preclinical and discovery phases of development.

ViiV Healthcare CEO Dominique Limet said: "As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry.

"As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry."

"The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV."

In a separate development, GSK is expanding its penicillin production plant in Irvine, Scotland.

The proposed expansion is expected to create nearly 55 new jobs.

This project is being backed by a £1.5m Scottish Enterprise Regional Selective Assistance (RSA) funding.

Image: GlaxoSmithKline head office, London. Photo: courtesy of Ian Wilson.